Hepatitis B virus (HBV) infection is a major risk factor worldwide for the development of hepatocellular carcinoma (HCC). Integrated HBV DNA fragments, often highly rearranged, are frequently detected in HCC. In woodchuck, the viral enhancer plays a central role in hepatocarcinogenesis, but in humans the mechanism of HBV oncogenesis has not been established. In this study we investigated the status of the viral enhancer in two human HCC cell lines, Hep3B and PLC/PRF/5 each containing one or more integrated HBV DNA fragments. Active enhancer was de®ned by virtue of its protein occupancy as determined by genomic in vivo DMS footprinting. In PLC/ PRF/5 cells, the HBV DNA was integrated in a cellular gene at chromosome 11q13, at a locus reported to be ampli®ed in many tumors. We show here that in both cell lines, the integrated HBV DNA fragments contain an active enhancer-I. In particular, the occupation of the two previously de®ned basic enhancer elements, E and EP, was prominent. While in both cell lines the same protein binds to the EP elements, the E element, however, is occupied in a cell-line speci®c manner. In PLC/PRF/5 but not Hep3B, the prominent binding of an unde®ned protein was detected. Our data suggest that this protein is likely to be the fetoprotein transcription factor (FTF). The ®nding that enhancer sequences are conserved and functional in dierent cell lines suggests a selection pressure for their long-term maintenance. We therefore propose that the HBV enhancer-I might play a role in hepatocellular carcinogenesis. Oncogene (2001) 20, 6811 ± 6819.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common human cancers. Epidemiological and other studies have established a relationship between the hepatitis B virus (HBV) carrier-state and development of HCC. HCC develops many years after HBV infection, strongly suggesting that no viral product directly causes cancer and thus that HBV does not encode a genuine transforming viral oncogene. Nevertheless, expression of viral proteins such as pX and PreS2/S has been associated with the development of HCC (reviewed in Butel et al., 1996; Hildt and Hofschneider, 1998) . Both proteins have been shown to coactivate a wide variety of cellular and viral promoters. The HBV pX protein either directly or indirectly modulates dierent signaling pathways that may give rise to cell growth and viability on one hand, and promote cell death on the other, depending on the experimental conditions. In addition, based on identi®cation of pX targets and biochemical analysis, it has been speculated that pX might modulate the cellular DNA repair machinery, thereby enhancing mutagenesis and transformation (Butel et al., 1996) . Nevertheless, in HBV positive HCC the p53 form present is frequently wild-type (Greenblatt et al., 1997) . A number of studies suggested that pX functionally inactivates p53 via several dierent mechanisms (Doitsh and Shaul, 1999 and the references therein). Interestingly, in woodchucks although no role has been attributed to pX in HCC development, the p53 gene is by large wild-type (Rivkina et al., 1996) . It remained to be clari®ed how p53 is inactivated in these tumors.
Integrated HBV DNA was found in a majority of HBV positive HCC, however the role of the integrants in hepatocarcinogenesis is not known. In many tumors, the HBV integrants contain a C-terminal truncated pX open reading frame (ORF) due to the integration`hot-spot' site in the HBV genome that is positioned at the end of the pX ORF. The truncated pX that often lacks the Cterminal 5 ± 15 amino acids might be a gain of function mutant that promotes oncogenesis. In this regard, it is interesting to note that the truncated pX becomes predominantly nuclear (Chami et al., 2000) . Interestingly, truncated pX can be also generated by an alternative mechanism that employs a cryptic polyadenylation signal inside the pX ORF (Kairat et al., 1999) .
Insertional activation of cellular proto-oncogenes by integration of cis-acting HBV elements has also been proposed. In woodchuck, integrated active enhancer is a hallmark of WHV oncogenesis. Site speci®c integration of woodchuck hepatitis virus (WHV) DNA next to proto-oncogenes is common (Fourel et al., 1994) . In these cases, the WHV integrants contain active enhancers (Flajolet et al., 1998) that are apparently essential in activating the nearby proto-oncogenes. However, the possibility that in these cases pX also contributes to oncogenesis was not ruled out. In humans, despite intensive searches, only few cases of HCC proved positive for proto-oncogene activation (Chami et al., 2000 and the references therein). The presence of an enhancer region in many HBV integrants is well established, but whether it is functional is an open question.
The mode of HBV gene expression is unique in the sense that the synthesis of all the viral transcripts is regulated predominantly at the transcriptional level and not by RNA processing (in sharp contrast to retroviruses, for example). Every single nucleotide of the viral DNA is engaged in at least one ORF, leaving no`coding-free' DNA segments exclusively devoted to regulation. Consequently, all the regulatory DNA cis elements, e.g. promoters, enhancers and the poly(A) signal, overlap with the existing ORFs. Furthermore, the regulatory cis-elements are sometimes bifunctional, as underscored by the fact that the deviated poly(A) box also has TATA-box function (Paran et al., 2000) . The viral genome contains multiple promoters whose activity is regulated mainly by enhancer-I and -II, the former positioned upstream, while the latter is inside the X ORF. This compact organization is the major reason for the diculty in separating the contribution of the enhancers from pX in oncogenesis.
The PLC/PRF/5 and Hep3B HCC cell lines contain integrated HBV sequences. PLC/PRF/5 (Alexander) cells contain multiple HBV integrants and are active in HBsAg production. The integrated HBV DNA fragments have been cloned and analysed (Shaul et al., 1984; Ziemer et al., 1985) . Seven dierent HBV integrants were identi®ed and none contained an intact pX ORF. Previously, it was shown that one of the PLC/PRF/5 integrants is positioned next to a cellular gene that encodes a ribosomal protein (Ou et al., 1987) . It has been speculated that the enhanced expression of this gene in PLC/PRF/5 cells might be attributed to the viral sequences. However insertional activation might not be the only model for transformation of these cells, and in fact, others have reported integration of HBV DNA in the cellular mevalonate kinase gene in PLC/ PRF/5 cells, resulting in the production of a chimeric preS2-mevalonate protein (Graef et al., 1994) .
One of the integrants, clone Al-26, contains a linear DNA sequence with an intact HBsAg gene. High production of HBsAg was obtained when CHO cells were transfected with this clone (unpublished observation). Production of HBsAg was also observed when SK-Hep1 cells were transiently transfected with clone Al-26. Furthermore, in that case removal of StuI ± SphI HBV fragment that contains the enhancer sequence resulted in a sharp reduction in HBsAg synthesis (Faktor et al., 1988) .
Here, we show that the Al-26 integrant is located in a chromosomal region that is ampli®ed in many tumors. By employing genomic DMS footprinting we show that these integrants contain active enhancer-I by virtue of their capacity to bind cellular DNA-binding proteins. Our data suggest that the integrated active HBV enhancer is preferentially maintained in HCC cells, and therefore might play a role in hepatocarcinogenesis.
Results
Structure of an HBV-DNA integrant of PLC/PRF/5 cells Clone Al-26, an HBV integrant in PLC/PRF/5 cells, was sequenced and was found to contain an intact HBsAg gene including the sequences of the known preS1 and preS2 promoters and the enhancer-I ( Figure  1 ). This integrant contains highly modi®ed enhancer-II sequence and the pX ORF contains a stop codon after the ®rst seven amino acids. Interestingly, this HBV sequence is integrated inside a cellular ORF between the coding and the promoter regions in an opposite orientation. The sequence of this ORF was reported (accession number HU79266), and based on in silico (bioinformatic) analysis, it might represent a nuclear protein involved in cell cycle regulation (data not shown). The intriguing possibility that this ORF has tumor suppressor function and that it is inactivated by the inserted HBV sequences deserves further study. This HBV integrant maps to the chromosomal region, 11q13 ( Figure 1 ), a region ampli®ed in many carcinomas (Shuster et al., 2000 and references therein) . We therefore investigated this integrant to determine whether its enhancer is active in vivo.
DMS footprinting of HBV enhancer-I
DMS footprinting detects the DNA G-residues that are in contact with the binding proteins. An occupied region is characterized by either lower or higher intensity of the bands cleaved at the G-residues, as compared with the corresponding naked DNA treated in a similar manner. Before performing genomic in vivo DMS footprinting, we analysed the HBV enhancer in vitro after incubation with PLC/PRF/5 cell nuclear extracts. To further analyse the protein binding regions, we employed HBV enhancer mutants at the sites of interest (Dikstein et al., 1990b) . When wt enhancer sequence was used as a probe, the G-residues at the E, NF1-binding site and EP regions were clearly detected ( Figure 2a ). When each of these binding sites were mutated, no G-residues were protected at the corresponding regions, suggesting that the interaction is speci®c and that this interaction is detectable by DMS footprinting.
The sequences of the integrated HBV enhancer of clone Al-26 of PLC/PRF/5 cells and the unique integrant of Hep3B cells were determined and compared to HBV adw2 subtype ( Figure 2b ). This enhancer sequence is highly conserved with minimal modi®cations. In sharp contrast, the enhancer II region was highly modi®ed (Berger and Shaul, 1987) .
Enhancer-I is occupied in vivo in PLC/PRF/5 cells
Having demonstrated that PLC/PRF/5 nuclear extracts occupy the HBV enhancer in vitro we next performed genomic DMS footprinting by the ligation-mediated polymerase chain reaction (LM ± PCR) technique, to assess enhancer occupancy in vivo. To this end we synthesized a number of oligonucleotides primers speci®c for clone Al-26. The analysis was performed on both the coding and the non-coding strands. The E element region was protected as was observed by the lower intensity of the G-residue at position 2600, and higher intensity bands at positions 2602 and 2596 (Figure 3, . This region was also protected when the coding strand was analysed. In that case, a speci®c reduction in the intensity of the Gresidues at the positions 2598 and 2601, and to a lesser extent at position 2595 were seen (Figure 3 coding  panel) . Interestingly, these very same residues were protected when an in vitro assay was performed ( Figure  2) suggesting that the same proteins may bind the enhancer region under both sets of conditions. However, in contrast to the in vitro analysis, the in vivo footprinting also detected DMS hyper-reactive Gresidues, suggesting that in vivo the E element encountered unique interactions or modi®cations.
The EP element was also DMS protected. Residues 2571 and 2568 are slightly protected, whereas residues 2564 and 2563 are fully protected. On the coding strand, residues 2562, 2566 and 2567 were protected. In the autoradiogram shown, the 2559 G-residue is not detected although sequence analysis con®rmed its presence in the Al-26 clone (Figure 2b) . In general the genomic footprinting pattern of the EP element is similar to that of in vitro data (Figure 2 ). In addition signi®cant protection is evident at the region between the EP and GB elements (2556 ± 2558); however, the nature of the binding protein is not known. Additional protected G-residues are located at the GB region in the non-coding strand, and at the HNF3-binding site at the coding strand. Interestingly, in vivo binding of a protein at the 5' region of the enhancer is clearly detected. This region was previously reported to be protected in vitro (Kosovsky and Siddiqui, 1999) .
HBV enhancer-I is inactive in heterologous cells
Clone Al-26 was transfected into CHO cells and stable cell lines were established that expressed high levels of HBsAg (data not shown). These cells were subjected to DMS footprinting to examine the behavior of the HBV enhancer under a heterologous environment. In contrast to our observations in PLC/PRF/5 cells, no signi®cant protection was detected (Figure 4) . The fact that no binding of the ubiquitous transcription factors, such as RFX1, was observed was rather surprising and may suggest that a large repertoire of binding protein is needed to establish a functional enhancer.
HBV enhancer-I in Hep3B cells is active in vivo
Genomic DMS footprinting of the enhancer region of the integrated HBV sequence in Hep3B was performed. Both the coding and the non-coding DNA strands were analysed. At the non-coding strand, the G-residue 2600 of the E element was protected, whereas residue 2596 was hyper-reactive to DMS ( Figure 5 ). In the coding strand, this region shows weak protection of the 2601 G-residue, which was not detected in PLC/PRF/5 cells either in vitro or in vivo.
The EP region is also occupied in Hep3B cells in vivo. In the non-coding strand, the G-residues 2571, 2568 and 2563 are protected, whereas in the coding strand, the protected residues are 2567, 2566, 2562 and 2559 ( Figure 5 ). This EP protected pattern is very similar to that obtained in the context of PLC/PRF/5 cells (Figure 3 ). Other protected G-residues are 2538 in the non-coding strand and 2533 in the coding strand, both mapped at the previously de®ned HNF3 binding site (Ori and Shaul, 1995) . Collectively, these data suggest that the HBV integrant in both cell lines are occupied by DNA binding proteins, however, the pattern of occupation is not identical.
FTF is a probable transcription activator of HBV enhancer-I
The sequence protected in PLC/PRF/5 cells at the 5' end of the enhancer, ACAAGGCCT, is very close to that of FTF binding site, TCAAGGTCA. An electrophoretic mobility shift assay (EMSA) was performed to examine the speci®city of the this DNA binding protein. Utilizing PLC/PRF/5 cells extract, speci®c band shifts were obtained that were competed out by the homologous probe but not by an oligonucleotide that contains the EP sequence (Figure 6a ). It has been reported that at 378C, FTF rapidly loses its capacity to bind DNA, whereas a preformed FTF-DNA complex is highly stable at this temperature (Galarneau et al., 1996) . Using this approach we further con®rmed the possibility that FTF binds enhancer-I (Figure 6a , lanes 5, 6). An oligonucleotides containing the putative HBV FTF binding site and the other containing the binding site found in a-fetoprotein promoter were synthesized and used in competition experiments (Figure 6b ). Both could eectively compete out the complex formed with the HBV enhancer-I putative FTF site (Figure 6c ).
These data strongly suggest that FTF or a related protein binds enhancer-I at its 5' end. To perform a functional analysis, the luciferase reporter gene under the HBV enhancer and the X promoter were used. The putative FTF site was mutated as shown in Figure 5b P end labeled at the 5' end and incubated with nuclear extracts (+lanes) prepared from PLC/PRF/5 cells and subjected to the DMS reaction. The products, after separation on a denatured urea polyacrylamide gel, are shown. Each of the reactive G-residues is numbered according to the numbering of the HBV genome. As template, we utilized the wt sequence, and mutants at the E element (E m ), at the NF1b site (NF1 m ) and at the EP region (EP m ). The mutated sequence in each case is indicated under the sequence of the wt. Previously, these fragments were utilized for DNasel footprinting and electromobility-shift-assays to show that in each case the binding of the corresponding proteins was abolished (Dikstein et al., 1990a) . The protected G-residues are marked by stars. (b) Sequence alignment of HBV enhancer-I (subtype adw2), Hep3B, and PLC/PRF/5. The previously identi®ed binding sites are marked above the sequence. Stars indicate nucleotide variations (FTFm). The mutant reporter displayed much lower activity in PLC/PRF/5 and Huh7 hepatoma cell lines but not in Hep3B cells (Figure 6d ). This ®nding is consistent with the lack of occupation of the FTF site in Hep3B ( Figure 5 ). These results strongly suggest that the FTF or a related protein is a functional activator of the HBV enhancer-I in PLC/PRF/5 cells, and that Hep3B cells do not express the protein at functional levels.
Discussion
In this study, HCC cell lines containing integrated HBV were utilized to determine whether the viral enhancer is active in vivo. Since the hallmark of an active enhancer is its interaction with speci®c DNA binding proteins, we adopted genomic in vivo DMS footprinting to address this issue. Two dierent cell lines, PLC/PRF/5 (Alexander) and Hep3B, were analysed. We found that each harbors the enhancer-I region with extremely high sequence conservation. Furthermore, the enhancers are active in vivo. Finally, the pattern of protein interaction is similar to that previously detected in cell free systems. The ®nding that enhancer sequences are conserved and functional in these cell lines suggests that there is selection pressure for their long-term maintenance. Based on this consideration we propose that the HBV enhancer-I might play a role in hepatocellular carcinogenesis (see below).
DMS footprinting permits identi®cation of the exact guanine residues that are in close contact with the binding proteins, and therefore is useful to determine the nature of the bound proteins as well. A major protected area corresponds to the previously characterized EP element. The protected G-residues are identical to that reported for the in vitro DMS footprinting of the EP (EF-C) element (Ostapchuk et al., 1989) , suggesting that the EP element in both cells bind at least the RFX1 protein (Blake et al., 1996; Katan et al., 1997; Siegrist et al., 1993) . In PLC/PRF/5 cells, the analysed EP element has an additional contact point with the binding protein at the non-coding strand due to a T to C transition. In vitro analysis of the E element revealed that it binds multiple activators, mostly of the bZip family (C/ EBP, AP1, CREB, ATFs). The genomic DMS footprinting of this element in PLC/PRF/5 cells shows a pattern of DMS protection similar to that of the AP1 occupation site (Konig, 1991) . A dierent occupation pattern is seen in Hep3B cells (Figure 7) . The fact that each cell line may utilize a dierent E-binding protein, is in agreement with our previous reports (Dikstein et al., 1990b) . At least some of the E-binding proteins are the very downstream targets of the cellular signaling pathway, and therefore, E element activity can be modulated by dierent external cues and environmental milieu (Faktor et al., 1990) . Interestingly, the E region in vivo shows strong DMS hyper-reactive Gresidues in both tested cell lines, which were not detected in vitro. This is likely to result from association with other proteins in a manner that is not recapitulated in vitro.
In addition, our in vivo analysis revealed that FTF or a related protein binds enhancer-I. Previously, it was shown that a protein of about 50 Kd that was named PBF interacts with this cis element sequence (Kosovsky and Siddiqui, 1999) . Given the fact that FTF binds and activates enhancer-II (Li et al., 1998 , Ishida et al., 2000 , Gilbert et al., 2000 , the role of this protein in HBV life cycle becomes signi®cant. FTF is an orphan nuclear receptor of the Drosophila fushi tarazu F1 (FTZ-F1) family. FTF is a liver enriched transcription factor that plays a role in regulation of liver speci®c genes. Both hepatocellular carcinoma cell lines analysed are active in production of HBsAg. In transfection experiments, the viral enhancer is important for supporting HBsAg production (Bulla and Siddiqui, 1988; Chang et al., 1987; Faktor et al., 1988) . The fact that both cell lines contain a functional enhancer lends further support to the role of the enhancer-I in driving HBsAg expression. It also has been reported that enhancer-II plays a role in regulating the synthesis of HBsAg (Zhou and Yen, 1990) . Our analysis however suggests that this enhancer is inactive in the PLC/PRF/ 5 cells (data not shown). Thus, enhancer-II has only a minor role if any in regulating HBsAg expression.
Ampli®cation of chromosomal band 11q13, where the HBV integrant Al-26 is mapped, is frequently observed in head and neck squamous carcinoma, oral squamous carcinoma, other digestive tract cancers, and breast carcinomas (Shuster et al., 2000 and references therein) . Additionally, signi®cant cases of HCC were reported to be ampli®ed at this chromosomal region (Kusano et al., 1999; Sakakura et al., 1999; Wong et al., 2000) , and a number of proto-oncogenes were mapped to this region. The fact that an HBV integrant with functional enhancer localized at this region might be important and may aect expression of a number of genes like the locus control regions (LCR). LCRs act at the level of chromatin remodeling and are necessary to ensure the establishment of an open chromatin con®guration at highly heterochromatic regions, such as the centeromeres (Kioussis and Festenstein, 1997). Integration of HBV within the satellitic sequences characteristic of ceneromeric regions was repeatedly reported (Miyaki et al., 2000; Shaul et al., 1986; Wang et al., 2001; Chen et al., 1994) . At least in one case the integrant is transcriptionally functional (Miyaki et al., 2000) , strongly arguing that the integrated HBV DNA, like LCR, can lead to the opening of the heterochromatic con®guration. According to this model, the HBV enhancer might have an intrinsic oncogenic function and therefore it might be considered as onco-DNA. The publication of the human genome sequence together with mapping of additional integrated HBV DNA in HCC samples will be instrumental for addressing this interesting possibility.
Materials and methods

Cell lines
PLC/PRF/5 (Alexander), and Hep3B cells were cultured in Dulbecco modi®ed Eagle's minimal essential medium (GIB-CO Laboratories) containing penicillin (100 U/ml) and streptomycin (100 mg/ml), supplemented with 8% fetal bovine serum.
In vitro DMS footprinting
For in vitro footprinting of HBV enhancers (either wt and mutants), the StuI(1115) ± SphI(1235) DNA fragment was 5' 32 P end labeled (5 ± 10610 6 c.p.m. per mg DNA) and incubated with nuclear extracts for binding reaction. The binding reactions were performed in 20 mM HEPES (pH 7.6), 150 mM NaCl, 0.1 mM EDTA, 0.05 mM ZnCl 2 , 2 mM dithiothreitol, 2610 4 c.p.m. of labeled DNA, 2 mg poly dIdC and 40 mg of nuclear proteins (Ben-Levy et al., 1989; Shaul and Ben-Levy, 1987) . After incubation on ice for Figure 7 Schematic representation of the distinct HBV enhancer elements and the protected G residues. The sequences of the indicated elements with the protected G-residues (open circles) or hyper-reactive residues (triangles) at both strands and in the two analysed cell lines are shown. In the case of the E element, the protection pattern is compared with that reported for the indicated binding factors in a context of dierent genes (Bossard et al., 1997; Datta et al., 2000; Konig, 1991) 30 min, 1 ml DMS (Sigma) was added and the reaction incubated for 40 s. After phenol-chloroform extraction and ethanol precipitation, the samples were exposed to piperidine at 908C for 30 min, ethanol precipitated and loaded on polyacrylamide urea sequencing gels.
In-vivo DMS footprinting
Monolayers of PLC/PRF/5, and Hep3B cells were cultured to subcon¯uence on 10 cm dishes. The cells were washed once with PBS at 378C and treated with 0.5% DMS in PBS at 378C for 2 min., then washed three times with PBS. DNA was extracted with TRI REAGENT (Molecular Research Center) according to the manufacturer's protocol. The extracted genomic DNA was cleaved at all methylated guanines by incubation in 1 M piperidine for 30 min at 908C, followed by ethanol precipitation, drying the DNA pellet, and resuspention in 100 ml of distilled water. Naked DNA from the same cells were subjected to DMS-piperidine cleavage and used as control.
DMS treated DNA was subjected to ligation-mediated PCR (LM ± PCR) as described previously (Hershkovitz and Riggs, 1997) . The oligonucleotides used for the analysis of the lower strand were: UP1: 5'-CCTTAATGCCTTTATAT-GC, UP2: 5'-ATATGCATGTATACAAGCAAAACAGGC, and UP3: 5'-ACAAGCAAAACAGGCTTTTACTTTCTCG. For the analysis of the upper-strand we used the following primers: DP1: 5'-GCAGTATGGATCGGC, DP2: 5'-CAAA-GGTTCCAGGCATGCGC, and DP3: 5'-TCCAGGCATGC-GCTGATGGCC. The asymmetric linker was identical to that previously described (Hershkovitz and Riggs, 1997) .
Electrophoretic mobility shift assays (EMSA)
Oligonucleotides used in EMSA were the following; HBV FTF: 5'-GATCCTTACAAGG CCTTTCTA, AFP: 5'-CTTA-TGTTCAAGGACAAAGACC, and EP: 5'-GATCCGTT-GCT CGGCAACGGCCTA. Nuclear extracts were prepared as described (Dignam et al., 1983) . Binding reactions and electrophoresis were performed as previously described (Galarneau et al., 1996) , with 1 ng of 32 P labeled probe, 5 mg PLC/PRF/5 nuclear proteins, and 10-or 100-fold molar excess of competitor oligonucleotides.
Luciferase assays
Cells were cultured and transfected as previously described (Haviv et al., 1995) . About 8 h before transfection, 2610 5 cells were plated per 3.5 cm dish. Each dish was transfected with 30 ng of luciferase reporter plasmid containing HBV enhancer and either wild-type or mutant FTF sites (as described in Figure 6b , d), and 1 mg of carrier DNA. 48 h post transfection, cells were harvested and assayed for luciferase activity.
